利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

9 条记录 (耗时 0.044 秒)

    7-piperidinoalkyl-3, 4-Dihydroquinolone derivative
    1.
    发明授权
    7-piperidinoalkyl-3, 4-Dihydroquinolone derivative 失效
    7-哌啶子基烷基-3,4-二氢喹诺酮衍生物

    公开(公告)号：US08461182B2

    公开(公告)日：2013-06-11

    申请号：US13122281

    申请日：2009-09-30

    申请人： Kosuke Kanuma ,  Naoki Miyakoshi ,  Madoka Kawamura ,  Tsuyoshi Shibata

    发明人： Kosuke Kanuma ,  Naoki Miyakoshi ,  Madoka Kawamura ,  Tsuyoshi Shibata

    IPC分类号： A61K31/04 ,  C07D215/38

    CPC分类号： C07D401/06 ,  C07D401/14

    摘要： PROBLEMTo provide a novel compound, a pharmaceutically acceptable salt or a hydrate thereof useful for preventing or treating for depression, anxiety disorders (such as generalized anxiety disorder, posttraumatic stress disorder, panic disorder, obsessive-compulsive disorder or social anxiety disorder), attention deficit disorder, mania, manic-depressive illness, schizophrenia, mood disorders, stress, sleep disorders, attacks, memory impairment, cognitive impairment, dementia, amnesia, delirium, obesity, eating disorder, appetite disorder, hyperphagia, bulimia, cibophobia, diabetes, cardiovascular diseases, hypertension, dyslipidemia, myocardial infarction, movement disorder (such as Parkinson's disease, epilepsy, convulsion or tremor), drug abuse, drug addiction or sexual dysfunction, based on a melanin-concentrating hormone receptor (MCH receptor) antagonistic action.SOLUTIONA compound, a pharmaceutically acceptable salt or a hydrate thereof represented by the formula (I).

    摘要翻译： 提供用于预防或治疗抑郁症，焦虑症（例如广泛性焦虑症，创伤后应激障碍，恐慌症，强迫症或社会焦虑症）的新型化合物，其药学上可接受的盐或水合物，注意力 缺陷障碍，躁狂症，躁狂抑郁症，精神分裂症，情绪障碍，压力，睡眠障碍，攻击，记忆障碍，认知障碍，痴呆，遗忘症，del妄，肥胖，进食障碍，食欲障碍，食欲过盛，贪食症， 基于黑色素浓度激素受体（MCH受体）拮抗作用的心血管疾病，高血压，血脂异常，心肌梗塞，运动障碍（例如帕金森病，癫痫，惊厥或震颤），药物滥用，药物成瘾或性功能障碍。 解决方案由式（I）表示的化合物，其药学上可接受的盐或其水合物。

    7-PIPERIDINOALKYL-3, 4-DIHYDROQUINOLONE DERIVATIVE
    3.
    发明申请
    7-PIPERIDINOALKYL-3, 4-DIHYDROQUINOLONE DERIVATIVE 失效
    7-哌啶二醇-3,4-二氢喹啉酮衍生物

    公开(公告)号：US20110178304A1

    公开(公告)日：2011-07-21

    申请号：US13122281

    申请日：2009-09-30

    申请人： Kosuke Kanuma ,  Naoki Miyakoshi ,  Madoka Kawamura ,  Tsuyoshi Shibata

    发明人： Kosuke Kanuma ,  Naoki Miyakoshi ,  Madoka Kawamura ,  Tsuyoshi Shibata

    IPC分类号： C07D401/10

    CPC分类号： C07D401/06 ,  C07D401/14

    摘要： Problem To provide a novel compound, a pharmaceutically acceptable salt or a hydrate thereof useful for preventing or treating for depression, anxiety disorders (such as generalized anxiety disorder, posttraumatic stress disorder, panic disorder, obsessive-compulsive disorder or social anxiety disorder), attention deficit disorder, mania, manic-depressive illness, schizophrenia, mood disorders, stress, sleep disorders, attacks, memory impairment, cognitive impairment, dementia, amnesia, delirium, obesity, eating disorder, appetite disorder, hyperphagia, bulimia, cibophobia, diabetes, cardiovascular diseases, hypertension, dyslipidemia, myocardial infarction, movement disorder (such as Parkinson's disease, epilepsy, convulsion or tremor), drug abuse, drug addiction or sexual dysfunction, based on a melanin-concentrating hormone receptor (MCH receptor) antagonistic action.Solution A compound, a pharmaceutically acceptable salt or a hydrate thereof represented by the formula (I).

    摘要翻译： 问题提供用于预防或治疗抑郁症，焦虑症（例如广泛性焦虑症，创伤后应激障碍，恐慌症，强迫症或社会焦虑症）的新型化合物，其药学上可接受的盐或水合物，注意力 缺陷障碍，躁狂症，躁狂抑郁症，精神分裂症，情绪障碍，压力，睡眠障碍，攻击，记忆障碍，认知障碍，痴呆，遗忘症，del妄，肥胖，进食障碍，食欲障碍，食欲过盛，贪食症， 基于黑色素浓度激素受体（MCH受体）拮抗作用的心血管疾病，高血压，血脂异常，心肌梗塞，运动障碍（例如帕金森病，癫痫，惊厥或震颤），药物滥用，药物成瘾或性功能障碍。 溶液由式（I）表示的化合物，其药学上可接受的盐或其水合物。

    Macrolide derivatives
    5.
    发明授权
    Macrolide derivatives 失效
    大环内酯衍生物

    公开(公告)号：US08124744B2

    公开(公告)日：2012-02-28

    申请号：US12299229

    申请日：2007-05-01

    申请人： Masato Kashimura ,  Madoka Kawamura ,  Toshifumi Asaka ,  Kiyoshi Takayama ,  Haruhisa Ogita

    发明人： Masato Kashimura ,  Madoka Kawamura ,  Toshifumi Asaka ,  Kiyoshi Takayama ,  Haruhisa Ogita

    IPC分类号： C07H17/08

    CPC分类号： C07H17/08 ,  A61K31/7048 ,  A61K31/7052 ,  C07H17/00

    摘要： Compounds represented by formula (I) and the formula (IV) have an inhibitory activity of MMP-9 production, therefore, are useful as a medicine agent with fewer side effects than conventional MMP enzyme activity inhibitors, as a prophylactic and therapeutic drug for oncogenic angiogenesis, chronic rheumatoid arthritis, vascular intimal thickening after a percutaneous coronary transluminal angioplasty, vascular atherosclerosis, hemorrhagic apoplexy, acute myocardial infarction, chronic heart failure, aneurysm, lung cancer metastasis, adult respiratory distress syndrome, asthma, interstitial pulmonary fibrosis, chronic rhinosinusitis, bronchitis or chronic obstructive pulmonary disease (COPD).

    摘要翻译： 由式（I）和式（IV）表示的化合物具有抑制MMP-9产生的活性，因此作为一种具有比常规MMP酶活性抑制剂更少副作用的药剂可用作致癌剂的预防和治疗药物 血管生成，慢性类风湿关节炎，经皮冠状动脉腔内血管成形术后血管内膜增厚，血管动脉粥样硬化，出血性中风，急性心肌梗塞，慢性心力衰竭，动脉瘤，肺癌转移，成人呼吸窘迫综合征，哮喘，间质性肺纤维化，慢性鼻鼻窦炎， 支气管炎或慢性阻塞性肺疾病（COPD）。

    MACROLIDE DERIVATIVES
    7.
    发明申请
    MACROLIDE DERIVATIVES 失效
    麦角糖衍生物

    公开(公告)号：US20090076253A1

    公开(公告)日：2009-03-19

    申请号：US12299229

    申请日：2007-05-01

    申请人： Masato Kashimura ,  Madoka Kawamura ,  Toshifumi Asaka ,  Kiyoshi Takayama ,  Haruhisa Ogita

    发明人： Masato Kashimura ,  Madoka Kawamura ,  Toshifumi Asaka ,  Kiyoshi Takayama ,  Haruhisa Ogita

    IPC分类号： C07H17/08

    CPC分类号： C07H17/08 ,  A61K31/7048 ,  A61K31/7052 ,  C07H17/00

    摘要： Compounds represented by formula (I) and the formula (IV) have an inhibitory activity of MMP-9 production, therefore, are useful as a medicine agent with fewer side effects than conventional MMP enzyme activity inhibitors, as a prophylactic and therapeutic drug for oncogenic angiogenesis, chronic rheumatoid arthritis, vascular intimal thickening after a percutaneous coronary transluminal angioplasty, vascular atherosclerosis, hemorrhagic apoplexy, acute myocardial infarction, chronic heart failure, aneurysm, lung cancer metastasis, adult respiratory distress syndrome, asthma, interstitial pulmonary fibrosis, chronic rhinosinusitis, bronchitis or chronic obstructive pulmonary disease (COPD).

    摘要翻译： 由式（I）和式（IV）表示的化合物具有抑制MMP-9产生的活性，因此作为一种具有比常规MMP酶活性抑制剂更少副作用的药剂可用作致癌剂的预防和治疗药物 血管生成，慢性类风湿关节炎，经皮冠状动脉腔内血管成形术后血管内膜增厚，血管动脉粥样硬化，出血性中风，急性心肌梗塞，慢性心力衰竭，动脉瘤，肺癌转移，成人呼吸窘迫综合征，哮喘，间质性肺纤维化，慢性鼻鼻窦炎， 支气管炎或慢性阻塞性肺疾病（COPD）。